Glucoryl-M4 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The extended-release formulation ensures sustained plasma concentrations, promoting improved patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glucoryl-M4 Forte is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is suitable for patients inadequately controlled on monotherapy or requiring combination therapy for optimal glycemic control. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver enzymes is recommended during therapy. This combination tablet offers a convenient and effective option for improving glycemic control in adults with type 2 diabetes mellitus.